Vyome at Chardan healthcare conference: lean biotech bets on rare wounds

On Tuesday, 20 October 2026, Vyome Therapeutics (HIND) showcased its strategy at Chardan's 10th Annual Healthcare Conference. The biotech firm highlighted its focus on capital efficiency, rare-disease development, and a lead program targeting malignant fungating wounds. This condition affects roughly 10% of advanced cancer patients and currently has no FDA-approved treatment.

Vyome presented early data for VT-1953, a topical gel intended for this condition. The company's pilot Phase II study involved 15 patients and demonstrated statistically significant odor reduction, alongside improvements in pain and psychological outcomes. The safety profile of VT-1953, tested in over 450 patients across five studies, has also been clean.

Vyome's CEO and co-founder, Venkat Nelabhotla, emphasized the company's emphasis on programs with significant unmet needs and lack of approved therapies. The firm adopts a lean development model aimed at conserving capital. They concentrate on immuno-inflammatory and rare diseases, pursuing VT-1953—a dual-action topical gel designed to inhibit bacterial DNA gyrase and block TLR inflammatory signaling.

This combination offers broader activity than the current off-label standard of care, metronidazole, which is ineffective against gram-positive bacteria.

The company's management maintains a simple capital structure with common stock only, and much of the backend work is handled by a CxO team in India to reduce costs. With only about $874,000 in second-quarter operating expenses, Vyome's lean operations contribute to its investment case. Despite its small team, the company is meeting public company reporting and regulatory requirements, holding more cash than debt on its balance sheet and maintaining a strong current ratio of 4.37.